Skip to main content
. Author manuscript; available in PMC: 2022 Feb 7.
Published in final edited form as: Mol Pharm. 2020 Oct 9;18(2):593–609. doi: 10.1021/acs.molpharmaceut.0c00474

Table 6.

Outcomes of IN DFO Treatment in Animal Models of ICH at Various Doses and Dosing Intervals

source animal model formulation dose administered dose detected in brain outcome
Hanson et al.91 MCAO maie Sprague— Dawley rats 10% solution of DFO in water delivered IN rats were pretreated 3X at 3 h intervals 48 h before MCAO with either 6 mg doses or 1.8 mg doses; p re treatment with a single 6 mg dose was also tested; 6 mg dose administered immediately after reperfusion, at 2 h, and at 4 h; 24 h after MCAO rats were dosed 3X at 3 h intervals 0.9–18.5 μM after 30 min 55% decrease in infarct volume in both pre- and post-treated rats; a 200- fold increase of DFO in the cortex relative to blood compared to IV delivery; decrease in post-ischemic weight loss in pretreated rats